Skip to Main content Skip to Navigation
Conference papers

O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

Abstract : no abstract
Document type :
Conference papers
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01162707
Contributor : Laurent Jonchère <>
Submitted on : Thursday, June 11, 2015 - 11:19:18 AM
Last modification on : Thursday, September 10, 2020 - 3:08:10 PM

Identifiers

Citation

M. Bourlière, P. Rabiega, N. Ganne-Carrie, L. Serfaty, P. Marcellin, et al.. O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial. The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. pp.S249, ⟨10.1016/S0168-8278(15)30131-8⟩. ⟨hal-01162707⟩

Share

Metrics

Record views

579